Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759437 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29908014 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL119553 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29928742 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL3724545 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29401176 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25185746 | 0.92 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25657518 | 0.92 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30422430 | 0.92 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL22636173 | 0.89 | MDM2 (0.60) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050215435-A1 | Phenylalanine derivatives as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-29 | — | — | US | disclosed |
| EP-1474381-B1 | PHENYLALANINE DERIVATIVES AS HERBICIDES | BASF AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1458746-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003057722-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| US-6548637-B1 | Endomorphine analog analgesics | SEPRACOR, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | NGLY1, CRH, NPY1R | MDM4 2721/4885TP53 2878/4885MDM2 2029/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | MDM4 4015/4885TP53 4139/4885MDM2 4244/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885MDM2 1604/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | MDM4 1577/4885TP53 11/4885MDM2 85/4885 |
| US-20050215435-A1 | Phenylalanine derivatives as herbicides | PAH, DDT, HPD | MDM4 2179/4885TP53 3009/4885MDM2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.